Literature DB >> 25153594

Role of lncRNAs in prostate cancer development and progression.

Melanie Weiss, Christoph Plass, Clarissa Gerhauser.   

Abstract

Prostate cancer (PCa) is the second most common cause of cancer-related deaths in men. Despite advances in the characterization of genomic and epigenetic aberrations contributing to PCa, the etiology of PCa is still far from being understood. Research over the past decade demonstrated the role of long non-coding RNAs (lncRNAs) in deregulation of target genes mainly through epigenetic mechanisms. In PCa, evidence accumulated that hundreds of lncRNAs are dysregulated. Functional analyses revealed their contribution to prostate carcinogenesis by targeting relevant pathways and gene regulation mechanisms including PTEN/AKT and androgen receptor signaling as well as chromatin remodeling complexes. Here we summarize our current knowledge on the roles of lncRNAs in PCa and their potential use as biomarkers for aggressive PCa and as novel therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25153594     DOI: 10.1515/hsz-2014-0201

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  16 in total

1.  Long non-coding RNA LINC00346, LINC00578, LINC00673, LINC00671, LINC00261, and SNHG9 are novel prognostic markers for pancreatic cancer.

Authors:  Baogang Zhang; Changfeng Li; Zhixia Sun
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

2.  Long noncoding RNAs and sulforaphane: a target for chemoprevention and suppression of prostate cancer.

Authors:  Laura M Beaver; Rachael Kuintzle; Alex Buchanan; Michelle W Wiley; Sarah T Glasser; Carmen P Wong; Gavin S Johnson; Jeff H Chang; Christiane V Löhr; David E Williams; Roderick H Dashwood; David A Hendrix; Emily Ho
Journal:  J Nutr Biochem       Date:  2017-01-12       Impact factor: 6.048

3.  MD-miniRNA could be a more accurate biomarker for prostate cancer screening compared with serum prostate-specific antigen level.

Authors:  Dong Xue; Cui-Xing Zhou; Yun-Bo Shi; Hao Lu; Xiao-Zhou He
Journal:  Tumour Biol       Date:  2015-01-05

4.  Long non-coding RNA BCAR4 promotes chondrosarcoma cell proliferation and migration through activation of mTOR signaling pathway.

Authors:  Xiaolong Shui; Chengwei Zhou; Wei Lin; Yang Yu; Yongzeng Feng; Jianzhong Kong
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-11

Review 5.  Impact of soy isoflavones on the epigenome in cancer prevention.

Authors:  Maria Pudenz; Kevin Roth; Clarissa Gerhauser
Journal:  Nutrients       Date:  2014-10-15       Impact factor: 5.717

6.  Exome-based genome-wide association study and risk assessment using genetic risk score to prostate cancer in the Korean population.

Authors:  Jong Jin Oh; Soo Ji Lee; Joo-Yeon Hwang; Dokyoon Kim; Sang Eun Lee; Sung Kyu Hong; Jin-Nyoung Ho; Sungroh Yoon; Joohon Sung; Wun-Jae Kim; Seok-Soo Byun
Journal:  Oncotarget       Date:  2017-07-04

7.  Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol.

Authors:  Raheem F H Al Aameri; Sandeep Sheth; Entkhab M A Alanisi; Vikrant Borse; Debashree Mukherjea; Leonard P Rybak; Vickram Ramkumar
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

8.  Long non-coding RNAs: new frontiers for advancing personalized cancer medicine in prostate cancer.

Authors:  Alireza Fotouhi Ghiam; Danny Vesprini; Stanley K Liu
Journal:  Transl Androl Urol       Date:  2017-04

Review 9.  Long Non-coding RNAs in Urologic Malignancies: Functional Roles and Clinical Translation.

Authors:  Jiajia Chen; Zhijun Miao; Boxin Xue; Yuxi Shan; Guobin Weng; Bairong Shen
Journal:  J Cancer       Date:  2016-08-15       Impact factor: 4.207

Review 10.  JAK-STAT signaling in cancer: From cytokines to non-coding genome.

Authors:  Jan Pencik; Ha Thi Thanh Pham; Johannes Schmoellerl; Tahereh Javaheri; Michaela Schlederer; Zoran Culig; Olaf Merkel; Richard Moriggl; Florian Grebien; Lukas Kenner
Journal:  Cytokine       Date:  2016-06-24       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.